Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
Timothy Chole, the Senior Vice President and Chief Commercial Officer of Rockwell Medical , Inc. (NASDAQ:RMTI), recently sold 2,868 shares of the company’s common stock. The transaction, executed on April 1, 2025, was part of a pre-established Rule 10b5-1 trading plan. Shares were sold at a weighted average price of $1.08, bringing the total transaction value to $3,097. Following this sale, Chole maintains ownership of 46,035 shares in the company. The micro-cap company, valued at $38.18 million, maintains a strong balance sheet with more cash than debt, according to InvestingPro analysis, which offers 14 additional key insights about RMTI’s financial health and valuation metrics in its comprehensive Pro Research Report.
In other recent news, Rockwell Medical reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $0.04, against a forecast of $0. The company also exceeded revenue expectations, achieving $24.7 million in Q4 compared to the anticipated $24.07 million. For the full year, Rockwell Medical’s net sales increased by 21% to $101.5 million. However, the company has projected a significant drop in 2025 revenue to between $65-70 million, primarily due to the transition of its largest customer to an alternative supplier. This shift is expected to result in a $34 million revenue loss compared to 2024. In response, Rockwell Medical is implementing expense reductions and remains in discussions with the customer for potential future commitments. Analysts at H.C. Wainwright have maintained a Buy rating on the stock but lowered the price target to $3.00, reflecting the anticipated impact on revenue growth. Despite these challenges, Rockwell Medical continues to explore growth opportunities, including international market expansion and new product launches.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.